|
GlaxoSmithKline initiates Phase III refractory asthma program
Equities.com The Phase III program includes two key studies: MEA115588: A 32-week multicenter, randomized, double-blind, double-dummy, placebo-controlled study in patients with severe uncontrolled refractory asthma. The primary endpoint of the study is to evaluate … Glaxo Starting Late-Stage Study of Asthma Drug GlaxoSmithKline starts final-stage tests on severe asthma drug GSK takes severe asthma antibody into phase III |
View full post on asthma – Google News